An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on the Multiple-Dose Pharmacokinetics of Ivacaftor and on the Multiple-Dose Pharmacokinetics of VX-661 Administered in Combination With Ivacaftor
Latest Information Update: 23 May 2014
At a glance
- Drugs Ciprofloxacin (Primary) ; Ivacaftor (Primary) ; Ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Vertex Pharmaceuticals
- 25 Mar 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Dec 2013 New trial record